Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Rasburicase Product Approval Information - Licensing Action 7/12/02

Proper name: Rasburicase
Tradename: Elitek
Manufacturer: Sanofi-Synthelabo, Inc, Malvern, PA, License #1294
Indication for Use: Initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid
Approval Date: 7/12/2002
Type of Submission: Biologics license application


Approval Letter (PDF)

Labeling (PDF)

Review 1 - Part 2 (PDFs)

Review 2 - (PDF)

Review 3 - (PDF)

Review 4 - (PDF)

Statistical Review - (PDF)

Page Last Updated: 09/30/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English